Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 6/20 | 0.89 |
| ▸ | VDR | P11473 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurochenodeoxycholate SCHEMBL19360984 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL20261730 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurursodiol SCHEMBL40764 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24001493 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL20204256 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24435723 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL56780 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24015433 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL56779 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL12917602 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172951-A1 | METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS | HOFFMAN TECHNOLOGIES LLC | 2023-06-08 | — | — | US | disclosed |
| US-20230172951-A1 | METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS | HOFFMAN TECHNOLOGIES LLC | 2023-06-08 | — | — | US | disclosed |
| WO-2021231934-A1 | METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS | HOFFMAN STEVEN (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231936-A1 | METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS | HOFFMAN STEVEN (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210353645-A1 | METHODS OF TREATING SARS-COV-2 INFECTIONS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-11-18 | — | — | US | disclosed |
| US-10905698-B1 | Methods of treating SARS-COV-2 infections | TYME, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-9904167-B2 | Compound, active light sensitive or radiation sensitive resin composition, resist film using same, resist-coated mask blank, photomask, pattern forming method, method for manufacturing electronic device, and electronic device | FUJIFILM CORPORATION (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20160116840-A1 | COMPOUND, ACTIVE LIGHT SENSITIVE OR RADIATION SENSITIVE RESIN COMPOSITION, RESIST FILM USING SAME, RESIST-COATED MASK BLANK, PHOTOMASK, PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172951-A1 | METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS | HAVCR2, NR1H4, SLC10A2 | GPBAR1 7/4885NR1H4 2/4885SLC10A2 3/4885 |
| US-10905698-B1 | Methods of treating SARS-COV-2 infections | ACE2, SARS1, ACE | GPBAR1 1629/4885NR1H4 1043/4885SLC10A2 87/4885 |
| US-20160116840-A1 | COMPOUND, ACTIVE LIGHT SENSITIVE OR RADIATION SENSITIVE RESIN COMPOSITION, RESIST FILM USING SAME, RESIST-COATED MASK BLANK, PHOTOMASK, PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND ELECTRONIC DEVICE | CHRM1, ESR1, RER1 | GPBAR1 2473/4885NR1H4 1113/4885SLC10A2 4867/4885 |
| US-20210353645-A1 | METHODS OF TREATING SARS-COV-2 INFECTIONS | ACE2, SARS1, ACE | GPBAR1 1629/4885NR1H4 1043/4885SLC10A2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.